Sanofi looks beyond blockbusters

Sanofi CEO Chris Viebacher (photo) wants his company to avoid the peaks and valleys that come with blockbuster drugs such as Lovenox, a $2 billion-a-year anti-clotting drug that's now facing generic competition. Instead, he's looking at emerging markets, consumer health products and generic medicines to help boost revenue, as well as focusing more on deals for drugs aimed at smaller patient groups. That may help explain Sanofi's interest in Genzyme--a biotech company that makes...

Report: Sanofi mulling $20B deal

Citing five unnamed people "with knowledge of the situation," Bloomberg is reporting that Sanofi-Aventis is mulling a potential $20 billion deal with a U.S. company. The news service says CEO Chris Viehbacher (photo) briefed the board this week in a special meeting. Any potential deal is in "very early stages" and could still fall through, according to sources. Sanofi refused to comment on the report. Of course, the rumor mill has already kicked into overdrive with speculation...

Sanofi CEO: Still in the hunt for new drug deals

Chris Viehbacher (photo) wasted little time in shaking things up at Sanofi-Aventis when he stepped in as CEO. Whipping out the company checkbook he has spent more than $9 billion on acquisitions, adding new programs and dropping others. And in an interview with Bloomberg he made it crystal clear that he's a long way from finished. "We've got one of the better pipelines in the industry one year later, and we're certainly not going to rest until we have the best pipeline," Viehbacher said. "We've...